Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
COLESTIPOL HYDROCHLORIDE vs AMINOSYN 10% (PH6)
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Binds bile acids in the intestine, forming an insoluble complex that is excreted in feces, thereby reducing enterohepatic circulation and increasing hepatic conversion of cholesterol to bile acids, lowering serum LDL cholesterol.
Aminosyn 10% is a parenteral amino acid solution that provides essential and non-essential amino acids for protein synthesis, helping to maintain nitrogen balance and support tissue repair and growth in patients unable to receive adequate nutrition enterally.
Primary hypercholesterolemia (FDA-approved adjunct to diet),Pruritus associated with partial biliary obstruction,Pseudomembranous enterocolitis (off-label, as colestipol binds Clostridium difficile toxins),Digitoxin toxicity (off-label, to interrupt enterohepatic circulation),Bile acid malabsorption (off-label)
Parenteral nutrition for prevention of nitrogen loss or treatment of negative nitrogen balance in patients where oral or enteral nutrition is impossible or insufficient
Initial: 5 g orally once daily or 2.5 g twice daily; increase gradually by 5 g/day at 1-2 month intervals; maintenance: 5-30 g/day divided once or twice daily; maximum: 30 g/day.
Intravenous infusion: 1 to 1.5 g/kg/day (equivalent to 10 to 15 m L/kg/day of 10% solution) for adult patients with normal nutritional status; adjust based on metabolic needs.
Not applicable as colestipol is not absorbed; it acts locally in the gastrointestinal tract and has no systemic half-life.
The terminal elimination half-life of individual amino acids varies (1–4 hours) depending on metabolic demand and renal function. For the amino acid mixture, the effective half-life is approximately 2 hours in patients with normal renal function. This short half-life necessitates continuous or frequent infusion to maintain stable plasma levels.
Not metabolized; not absorbed systemically.
Amino acids are metabolized through deamination, transamination, and decarboxylation pathways, primarily in the liver, with nitrogen converted to urea via the urea cycle and carbon skeletons entering the Krebs cycle.
Colestipol hydrochloride is not absorbed systemically; it is excreted entirely in the feces as the intact polymer, without undergoing metabolism. No renal or biliary elimination occurs.
Amino acids from Aminosyn 10% are primarily utilized for protein synthesis and metabolic processes. Excess nitrogen is eliminated via the kidneys as urea (renal elimination accounts for >90% of nitrogen excretion). Minimal biliary/fecal elimination (<5%) occurs via unabsorbed amino acids in patients with malabsorption. In renal impairment, elimination is reduced.
Not applicable; the drug is not absorbed and does not bind to plasma proteins.
Amino acids exhibit low protein binding (<10%) to plasma proteins (primarily albumin). High-affinity binding is negligible; most amino acids circulate freely.
Not applicable; colestipol is not absorbed and remains within the gastrointestinal lumen.
Volume of distribution (Vd) for amino acids in Aminosyn 10% ranges from 0.3–0.5 L/kg, approximating total body water. This reflects extensive distribution into extracellular and intracellular compartments.
0% for systemic absorption; it is non-absorbable and acts locally in the intestine.
Bioavailability is 100% when administered intravenously. Not applicable for oral, intramuscular, or other routes; Aminosyn 10% is for IV use only.
No specific dose adjustment recommended; use with caution in severe renal impairment due to potential for hyperchloremic metabolic acidosis.
For GFR 30-59 m L/min: reduce dose to 0.8-1.0 g/kg/day. For GFR 15-29 m L/min: 0.6-0.8 g/kg/day. For GFR <15 m L/min or dialysis: 0.5-0.6 g/kg/day; monitor for azotemia.
No specific dose adjustment recommended; caution in severe hepatic impairment due to possible decreased cholesterol synthesis.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 30-50% and use a formulation with higher branched-chain amino acids. Child-Pugh Class C: avoid or use with extreme caution, adjust based on ammonia levels.
Not established for children <10 years; for ≥10 years, initial: 5 g orally once daily; increase gradually to 5-20 g/day divided once or twice daily.
Infants (0-1 year): 2-3 g/kg/day (20-30 m L/kg/day). Children (1-12 years): 1.5-2.5 g/kg/day (15-25 m L/kg/day). Adolescents: 1-1.5 g/kg/day (10-15 m L/kg/day). Administer as continuous IV infusion.
No specific dose adjustment; monitor for gastrointestinal adverse effects and potential interactions with other medications due to altered GI motility and polypharmacy.
Initiate at lower end of dosing range (0.8-1 g/kg/day) due to reduced renal function and increased risk of fluid overload; monitor serum electrolytes and renal function closely.
No FDA black box warning.
None
May cause hypertriglyceridemia,Risk of vitamin K deficiency and bleeding (due to bile acid binding),May impair absorption of fat-soluble vitamins (A, D, E, K),May cause constipation or fecal impaction (especially in elderly),May interfere with absorption of other drugs (e.g., warfarin, thyroid hormones, digoxin); separate administration by at least 1 hour or as specified
Risk of hyperammonemia, especially in patients with hepatic impairment,Risk of metabolic acidosis,Risk of fluid overload and electrolyte imbalances,Monitor for signs of infection or phlebitis at infusion site,Use with caution in patients with renal insufficiency as may worsen azotemia
Hypersensitivity to colestipol hydrochloride or any component,Complete biliary obstruction,Phenylketonuria (if formulation contains aspartame)
Hypersensitivity to any component,Inborn errors of amino acid metabolism (e.g., maple syrup urine disease),Severe hepatic failure with encephalopathy,Severe azotemia or anuria
Colestipol can bind to dietary fats and fat-soluble vitamins (A, D, E, K). Take supplements at least 1 hour before or 4-6 hours after colestipol. High-fiber foods may reduce binding but are generally encouraged to prevent constipation. Avoid grapefruit juice? No significant interaction.
No specific food interactions. However, since this is used in parenteral nutrition, oral intake may be contraindicated. Adjustments may be needed if transitioning to oral feeding.
Colestipol hydrochloride is not absorbed systemically, thus no direct fetal exposure. No teratogenic risk expected. First trimester: minimal risk. Second/third trimester: no known adverse fetal effects.
Amino acids are essential nutrients; no teratogenic risk is known when used at recommended doses. However, safety during pregnancy has not been established through controlled studies. First trimester: No evidence of fetal harm. Second/third trimester: Use only if clearly needed; monitor maternal and fetal status.
Colestipol is not absorbed systemically and not excreted into breast milk. Compatible with breastfeeding. M/P ratio not applicable.
Excretion of amino acids into breast milk is not well studied. Considering the endogenous nature of amino acids, risk to infant is likely low if used at recommended doses. M/P ratio not determined.
No dose adjustment required due to lack of systemic absorption. Monitor for potential fat-soluble vitamin deficiency and supplement if needed.
No specific dose adjustments required. Pregnancy may alter fluid and electrolyte needs; individualize dosing based on clinical status and laboratory parameters.
Colestipol hydrochloride is a bile acid sequestrant used as adjunctive therapy for primary hyperlipidemia. It may increase triglyceride levels; monitor triglycerides before initiation. Administer other medications 1 hour before or 4-6 hours after colestipol to reduce absorption interference. Use with caution in constipation-prone patients; encourage high-fiber diet and adequate fluid intake. Can bind thyroxine, warfarin, digoxin, and fat-soluble vitamins.
Aminosyn 10% (p H 6) is a crystalline amino acid solution used for parenteral nutrition. Monitor serum electrolytes, BUN, and ammonia levels due to risk of metabolic abnormalities. Adjust infusion rate to avoid hyperglycemia or hypoglycemia. Use with caution in renal or hepatic impairment. Check for compatible additives and avoid mixing with lipids in the same container unless validated.
Take colestipol with meals and plenty of water (at least 8 oz).,Do not take other medications within 1 hour before or 4-6 hours after colestipol.,May cause constipation; increase dietary fiber and fluid intake.,Report severe constipation, abdominal pain, or unusual bleeding.,Continue prescribed diet and exercise regimen.,Store at room temperature; do not freeze.
Report any signs of infection at the IV site, such as redness, swelling, or pain.,Inform your healthcare provider if you experience nausea, vomiting, or dizziness.,This solution provides essential nutrients; do not stop treatment without consulting your doctor.,Keep an eye on your blood sugar levels if you have diabetes.,Do not take any other nutritional supplements without medical advice.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about COLESTIPOL HYDROCHLORIDE vs AMINOSYN 10% (PH6), answered by our medical review team.
COLESTIPOL HYDROCHLORIDE is a Bile Acid Sequestrant that works by Binds bile acids in the intestine, forming an insoluble complex that is excreted in feces, thereby reducing enterohepatic circulation and increasing hepatic conversion of cholesterol to bile acids, lowering serum LDL cholesterol.. AMINOSYN 10% (PH6) is a Parenteral Nutrition Solution that works by Aminosyn 10% is a parenteral amino acid solution that provides essential and non-essential amino acids for protein synthesis, helping to maintain nitrogen balance and support tissue repair and growth in patients unable to receive adequate nutrition enterally.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between COLESTIPOL HYDROCHLORIDE and AMINOSYN 10% (PH6) depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of COLESTIPOL HYDROCHLORIDE is: Initial: 5 g orally once daily or 2.5 g twice daily; increase gradually by 5 g/day at 1-2 month intervals; maintenance: 5-30 g/day divided once or twice daily; maximum: 30 g/day.. The standard adult dose of AMINOSYN 10% (PH6) is: Intravenous infusion: 1 to 1.5 g/kg/day (equivalent to 10 to 15 m L/kg/day of 10% solution) for adult patients with normal nutritional status; adjust based on metabolic needs.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between COLESTIPOL HYDROCHLORIDE and AMINOSYN 10% (PH6) in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. COLESTIPOL HYDROCHLORIDE is classified as Category C. Colestipol hydrochloride is not absorbed systemically, thus no direct fetal exposure. No teratogenic risk expected. First trimester: minimal risk. Second/third trimester: no known . AMINOSYN 10% (PH6) is classified as Category C. Amino acids are essential nutrients; no teratogenic risk is known when used at recommended doses. However, safety during pregnancy has not been established through controlled studi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.